Reimbursement variation across member states

Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did.

Asking about reimbursement variation across member states directly, because I have read four threads on it and each answered a slightly different question.

The version I want answered is the narrow one: given the method stated below, is the result within what anyone else has seen? I am not asking what it means yet.

Method, numbers and the two assumptions I am aware of making are below. If the assumptions are wrong that is more useful to me than agreement.

Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them.

The part I am sure of is shorter than the part I have written.

Second this, and I would have said it less carefully.

This follows the opening post rather than contradicting it.

Cost comparisons across member states should state what is included, because the components bundled into a price differ.

Coming back to the opening post, because the follow-up matters more than the original answer.

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

Post #5 is right about the mechanism and I think understates the practical bit.

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

Genuinely open to being wrong about this one.

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.

Movement of medicines between member states for personal use has rules, and they are published rather than a matter of custom.

Two people can read the same figure differently here and both be reasonable.

The arithmetic in post #9 is right; the assumption feeding it is the part to check.

Say which member state. A statement true in one is regularly false in another and the difference is not marginal.

Where a member reports an access decision, the stated criterion is the generalisable part and the outcome is not.

Reading it again, the caveat matters more than the finding.

Post #8 and I disagree about the size of the effect, not about the direction.

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

It is worth checking rather than assuming, which costs nothing.